| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656566.2011.605354 |
| P698 | PubMed publication ID | 21967344 |
| P2093 | author name string | Constantin A Dasanu | |
| Antarpreet Kaur | |||
| P2860 | cites work | Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 |
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy | Q28242840 | ||
| EGF receptor | Q28646107 | ||
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer | Q33389302 | ||
| Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. | Q33751191 | ||
| Kinase inhibitors in cancer therapy: a look ahead | Q33897202 | ||
| Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer | Q34527500 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies | Q35179415 | ||
| HER1/EGFR targeting: refining the strategy | Q35644830 | ||
| The role of HER2/neu expression and trastuzumab in non-small cell lung cancer | Q35674579 | ||
| Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer | Q35809752 | ||
| The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors | Q36334739 | ||
| Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma | Q36611021 | ||
| Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma | Q36696088 | ||
| Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line | Q36911274 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| Cardiotoxicity profile of trastuzumab | Q37165488 | ||
| Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer | Q37360162 | ||
| AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo | Q39745596 | ||
| Trastuzumab in gastric cancer | Q39864629 | ||
| Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. | Q40216149 | ||
| HER-2/neu amplification is an independent prognostic factor in gastric cancer. | Q40303656 | ||
| Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma | Q40401124 | ||
| Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor | Q41067751 | ||
| Targeted HER2 treatment in advanced gastric cancer | Q43148962 | ||
| In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways | Q44250297 | ||
| Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer | Q44265943 | ||
| Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer | Q44480885 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
| A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. | Q51763771 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q51779078 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. | Q53443853 | ||
| EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. | Q53810400 | ||
| Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. | Q54398738 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 2493-2503 | |
| P577 | publication date | 2011-10-04 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma | |
| P478 | volume | 12 |
| Q36770491 | Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer |
| Q35998729 | Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models |
| Q41205623 | Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis |
| Q51219045 | Genetics of gastric cancer. |
| Q47764668 | Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis |
| Q38075499 | Metastatic gastric cancer treatment: a little slow but worthy progress |
| Q95728277 | Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population |
| Q34222369 | Whole exome sequencing of pediatric gastric adenocarcinoma reveals an atypical presentation of Li-Fraumeni syndrome |
Search more.